uniQure (NASDAQ:QURE) Shares Gap Down – Should You Sell?

Shares of uniQure (NASDAQ:QURE) gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with a volume of 41,727 shares traded.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on QURE. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Royal Bank of Canada increased their price target on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Leerink Partners boosted their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. StockNews.com raised uniQure to a “sell” rating in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group lifted their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Price Performance

The stock has a 50-day moving average of $10.38 and a two-hundred day moving average of $7.62. The firm has a market cap of $874.45 million, a price-to-earnings ratio of -3.62 and a beta of 0.41. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. On average, analysts anticipate that uniQure will post -3.82 EPS for the current year.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of QURE. abrdn plc boosted its position in uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after acquiring an additional 1,528,581 shares during the period. Franklin Resources Inc. purchased a new stake in shares of uniQure in the third quarter worth approximately $7,360,000. Point72 Asset Management L.P. boosted its holdings in shares of uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares during the period. FMR LLC grew its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Finally, Privium Fund Management B.V. increased its stake in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 104,500 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.